Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Dulaney

Orthopaedic Surgery West Des Moines, IA Medical Doctor

NPI 1942264346 CMS profile 315120

6001 Westown Pkwy, West Des Moines, IA 50266

Open in the dashboard

General payments

$401

8 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Dulaney of West Des Moines, IA is reported in the CMS Open Payments database as having received $401 across 8 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 20th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $165 3
2021 General $48 2
2020 General $131 2
2019 General $57 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Dulaney
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Thomas Dulaney were reported at $165. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Thomas Dulaney Orthopaedic Surgery median Middle half National median
2019 $57 $644 $140–$2,844 $163
2020 $131 $312 $75–$1,860 $114
2021 $48 $520 $117–$2,495 $132
2022 $0 $598 $128–$2,731 $149
2023 $0 $461 $128–$2,264 $160
2024 $0 $497 $134–$2,475 $164
2025 $165 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. DePuy Synthes Sales Inc. $153 2 payments
  2. Zimmer Biomet Holdings, Inc. $131 2 payments
  3. Medical Device Business Services, Inc. $48 2 payments
  4. Biocomposites Inc $35 1 payment
  5. Sanara MedTech Inc. $35 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $401 8 payments
Products named General payments · program years 2019–2025
  1. ATTUNE Ortho-Knee $144 3 payments
  2. Persona Revision $131 2 payments
  3. ATTUNE Ortho-Knee $57 1 payment
  4. Stimulan $35 1 payment
  5. CellerateRx $35 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

453

Median for Orthopedic Surgery: 203

Drug cost

$3,677

Median for Orthopedic Surgery: $1,433

Branded share of claims

35.5%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 150 $1,720
Mupirocin Generic 145 $909
Doxycycline Hyclate Generic 13 $506
Cefadroxil Generic 20 $258
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 11 $134
Tramadol Hcl Generic 26 $76
Amoxicillin Generic 68 $55
Clindamycin Hcl Generic 20 $19

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$252,301

Of which drugs: $12,815

Medicare patients

644

Average age 75

Services billed

5,956

406 women, 238 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Depression 29%
Chronic kidney disease 25%
Diabetes 22%
Ischemic heart disease 22%
Atrial fibrillation 17%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 17 1,262 $6,655
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 268 2,367 $1,647

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

8 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record